Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | LPO | P22079 | 2/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | LTK | P29376 | 1/20 | 0.34 |
| ▸ | GRK5 | P34947 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306662 | 0.80 | HSP90AA1 (0.39) | KMT2AMAP4K4ABL1KDRBCHE | |
| SCHEMBL165474 | 0.78 | KMT2A (0.38) | KMT2AF2ALOX15LPOSCN4A | |
| SCHEMBL12128384 | 0.78 | PLAU (0.51) | KMT2AF2ALOX15LPOHPGD | |
| SCHEMBL3604417 | 0.78 | — | — | |
| SCHEMBL4106091 | 0.75 | — | — | |
| SCHEMBL1044057 | 0.75 | — | — | |
| SCHEMBL13101034 | 0.73 | MAPT (0.33) | KMT2AALOX15MAP4K4METHPGD | |
| SCHEMBL19654963 | 0.69 | KMT2A (0.55) | KMT2AF2LPOP2RX4JMJD6 | |
| SCHEMBL184357 | 0.69 | KDM4E (0.40) | KMT2AHPGDKDM4EALDH1A1GAA | |
| SCHEMBL21896802 | 0.69 | SCN4A (0.50) | KMT2ASCN4AHPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| CN-101952287-B | Protein kinase inhibitors and use thereof | MERCK SERONO SA | 2013-11-27 | — | — | CN | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| CN-101952287-A | Kinases inhibitor and application thereof | MERCK SERONO SA | 2011-01-19 | — | — | CN | disclosed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
| EP-0980374-B1 | PHOSPHODIESTERASE 4-INHIBITING DIAZEPINOINDOLONES | PFIZER HOLDING FRANCE (FR) | 2003-02-12 | — | — | EP | disclosed |
| US-6239130-B1 | ASTHMA, ATOPIC DERMATITIS, RHEUMATOID ARTHRITIS, INFLAMMATORY BOWEL DISORDERS, PULMONARY HYPERTENSION, LIVER INJURY, BONE LOSS, SEPTIC SHOCK, OR MULTIPLE SCLEROSIS, | WARNER-LAMBERT COMPANY | 2001-05-29 | — | — | US | disclosed |
| EP-0980374-A1 | PHOSPHODIESTERASE 4-INHIBITING DIAZEPINOINDOLONES | PARKE-DAVIS (FR) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998049169-A1 | PHOSPHODIESTERASE 4-INHIBITING DIAZEPINOINDOLONES | PARKE-DAVIS (FR) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | KMT2A 2055/4885F2 4663/4885ALOX15 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.